NCT05752123Terminated
A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.
A Single Site, Open Label Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassemia
Source: ClinicalTrials.gov · Last updated 30 Mar 2025
Brief summary (registry, in English)
This is an open label, single site study to evaluate the safety and Efficacy of ET-01 Transplantation in subjects with Transfusion Dependent β-Thalassaemia.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 2 (actual)
- First submitted
- 16 Feb 2023
- Start date
- 18 Feb 2023
- Primary completion date
- 29 Jan 2024
- Lead sponsor
- EdiGene (GuangZhou) Inc.
- Diseases
- Thalassaemia
- NCT number
- NCT05752123
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior allo-HSCT or gene therapy.
- Other protocol defined Exclusion criteria may apply.
Other illness
- Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg and HBV DNA positive, HCV DNA positive, or Treponema Pallidum infection;
Other
- Subjects with associated α-thalassemia;
- HLA identical sibling or unrelated donors are available;
Who the study is looking for
- Subject and/or subject's legal personal representative fully understand and voluntarily sign informed consent forms;
- 6~35 years old, all gender;
- Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol;
- Eligible for autologous stem cell transplant;
- Organs in good function.
- Other protocol defined Inclusion criteria may apply.
Age in the registry: 6 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PLA 923 Hospital Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.